A DNA-Based Method to Assay Total and Infectious Particle Contents and Helper Virus Contamination in High-Capacity Adenoviral Vector Preparations
- 1 July 2002
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 13 (10) , 1151-1156
- https://doi.org/10.1089/104303402320138934
Abstract
High-capacity adenoviral (HC-Ad) vectors are devoid of all viral genes. Therefore, these vectors feature reduced toxicity, immunogenicity, and increased capacity for foreign DNA. HC-Ad vectors are produced in E1-transformed cell lines in the presence of an E1-deleted helper virus that provides in trans all viral functions necessary for vector production. By cre/loxP- or FLPe/Frt-mediated recombination the packaging signal of the helper virus is excised during vector production resulting in nonpackagable helper virus genomes. Although recombinase-mediated excision of the packaging signal from the helper virus genome is highly efficient, a small number of helper virus genomes with retained packaging signals are still packaged into capsids. For clinical trials, HC-Ad vector preparations have to be characterized accurately with respect to the number of (1) total HC-Ad vector particles, (2) infectious HC-Ad vector particles, and (3) the number of contaminating helper virus particles. We describe a fast and versatile DNA-based biologic assay for determination of these three parameters by standard laboratory methods. This assay is a useful tool for determining bioactivity data of adenoviral vector preparations and, importantly, allows their comparison among different studies.Keywords
This publication has 24 references indexed in Scilit:
- Targeting of High-Capacity Adenoviral VectorsHuman Gene Therapy, 2001
- Development of a FLP/frt System for Generating Helper-Dependent Adenoviral VectorsMolecular Therapy, 2001
- Sequestration of Adenoviral Vector by Kupffer Cells Leads to a Nonlinear Dose Response of Transduction in LiverMolecular Therapy, 2001
- In Vivo Dose Threshold Effect of Adenovirus-Mediated Factor VIII Gene Therapy in Hemophiliac MiceMolecular Therapy, 2000
- Prolonged Expression and Effective Readministration of Erythropoietin Delivered with a Fully Deleted Adenoviral VectorHuman Gene Therapy, 2000
- High-Capacity Adenoviral Vectors for Gene Transfer and Somatic Gene TherapyHuman Gene Therapy, 1999
- DNA from Both High-Capacity and First-Generation Adenoviral Vectors Remains Intact in Skeletal MuscleHuman Gene Therapy, 1999
- High Doses of a Helper-Dependent Adenoviral Vector Yield Supraphysiological Levels ofα1-Antitrypsin with Negligible ToxicityHuman Gene Therapy, 1998
- Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicityNature Genetics, 1998
- Stepwise dismantling of adenovirus 2 during entry into cellsCell, 1993